Moderna's stock experienced a sharp decline of up to 25% on Thursday after partial data from its cancer vaccine trial was leaked prematurely. This vaccine, developed in partnership with Merck, generated significant attention as it represents a personalized treatment approach for melanoma patients. Despite the initial negative market reaction, the full data released later that day demonstrated promising outcomes, surpassing expectations by reducing the risk of cancer recurrence or death by 42% when combined with Merck’s Keytruda immunotherapy.

The vaccine, called intismeran autogene, showed substantial improvements in patient survival without melanoma recurrence, with 82% of treated patients alive and cancer-free at two years, compared to 70% with Keytruda alone. Additional analysis indicated a 38% risk reduction of cancer spreading or death. Experts like Dr. Hussein Tawbi at MD Anderson Cancer Center highlighted the significance of these results, noting the vaccine’s added benefit and mild side effect profile compared to existing treatments.

Merck’s Research Laboratories president, Dr. Dean Li, emphasized the difficulty of showing further benefits when pairing therapies with an already effective drug like Keytruda, yet these trial results demonstrated clear additional efficacy. The companies are continuing studies across other cancers, such as lung and bladder, though broader effectiveness remains to be proven. Moderna CEO Stéphane Bancel confirmed plans to submit the vaccine for regulatory approval next year, marking a major milestone toward bringing this personalized therapy to market.

While investors’ high expectations may have contributed to the steep stock drop, analysts agree the clinical data is strong and meaningful. The personalized nature of the vaccine requires a complex manufacturing process that currently takes about six weeks, although efforts are underway to shorten this timeline. This cancer vaccine could become an important addition to Moderna’s portfolio, complementing its established vaccines for Covid-19, flu, and respiratory illnesses, and potentially revolutionizing cancer treatment with individualized immune responses.